Showing 901-910 of 951 results for "".
- Socioeconomic Status Affects Cognition and Dementiahttps://practicalneurology.com/news/effects-of-socioeconomic-status-on-cognition-and-dementia-1/2469985/At the Alzheimer Association International Conference 2022 (AAIC2022) in San Diego, CA and online, multiple studies showing the impact socioeconomic status and other social determinants of health on cognitive health, dementia, and Alzheimer disease were presented. Perceived n
- Multimodal Approaches to Reducing Dementia Riskhttps://practicalneurology.com/news/multimodal-approaches-to-reducing-dementia-risk/2469978/Recent evidence suggests dementia risk is modifiable, and that a 5% to 20% reduction in individual modifiable risk factors (eg, smoking cessation, physical activity, diet, and cognitive activity) could reduce dementia incidence by as much as 40%. Some risk factors, however, are not modifiable at
- Diazepam Nasal Spray Treatment Increases Time Interval Between Seizure Clustershttps://practicalneurology.com/news/diazepam-nasal-spray-treatment-increases-time-interval-between-seizure-clusters/2469906/In post hoc analysis of a repeat dose study (NCT02721069), diazepam nasal spray (Valtoco; Neurelis, San Diego, CA) was shown to have increased the times between seizure clusters in individuals wit
- Trofinetide Demonstrates Efficacy and Safety for Treating Rett Syndromehttps://practicalneurology.com/news/trofinetide-demonstrates-efficacy-and-safety-for-treating-rett-syndrome/2469883/In a phase 3 study (NCT04181723), participants with Rett syndrome who were treated with trofinetide (Acadia Pharmaceuticals, San Diego, CA) vs placebo had statistically significant improvements in the core symptoms of Rett syndrome, in
- Valbenazine Shows Efficacy for Chorea in Huntington Disease and Is Safe and Effective for Treatment of Tardive Dyskinesia in People Over Age 65https://practicalneurology.com/news/valbenazine-shows-efficacy-for-chorea-in-huntington-disease-and-is-safe-and-effective-for-treatment-of-tardive-dyskinesia-in-people-over-age-65/2469880/Valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA) is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment of tardive dyskinesia (TD) that is available as a once-daily dose and does not require titration. Valbenazine can be dosed at 40, 60, or 8
- Diazepam Nasal Spray for Acute Treatment of Seizure Clusters Easy to Use and Maintained Quality of Lifehttps://practicalneurology.com/news/diazepam-nasal-spray-for-acute-treatment-of-seizure-clusters-easy-to-use-and-maintained-quality-of-life/2469878/**This article was updated on April 13, 2022 to correct an error regarding the relative bioavailability of diazepam nasal spray (Valtoco; Neurelis, San Diego, CA) compared with other formulations of diazepam. New data from the clinical development program for diazepam nasal spr
- Cerebrospinal Fluid Diagnostic Test for Synucleinopathies Now Availablehttps://practicalneurology.com/news/cerebrospinal-fluid-diagnostic-test-for-synucleinopathies-now-available/2469865/A new, first-in-class laboratory test (Syntap; Amprion, San Diego, CA) has become available that provides accurate measurement of misfolded α-synuclein aggregates in cerebrospinal fluid (CSF). The test is certified by Clinical Laboratory and Improvement Amendments (CLIA) and Clinical Associ
- High Interest in Gene Therapy for Painful Diabetic Neuropathyhttps://practicalneurology.com/news/high-interest-in-gene-therapy-for-painful-diabetic-neuropathy/2469849/A press release notes that results from a phase 3 study (NCT04087941) of gene therapy, donaperminogene seltoplasmid (VM202; Helixmith, San Diego, CA), for painful diabetic therapy is among the mos
- Valbenazine Reduced Chorea Associated With Huntington Diseasehttps://practicalneurology.com/news/valbenazine-reduced-chorea-associated-with-huntington-disease/2469775/In a phase 3 study (NCT04102579), participants with Huntington disease (HD) treated with valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA) had a reduction in chorea severity. Chorea re
- Phase 3 Study of Tolperisone for Muscle Spasms Completes Enrollmenthttps://practicalneurology.com/news/phase-3-study-of-tolperisone-for-muscle-spasms-completes-enrollment/2469759/Enrollment of 1,000 participants is complete for the phase 3 RESUME-1 study (NCT04671082) of tolperisone (Mydocalm; Neurana Pharmaceuticals, San Diego, CA) for muscle spasms associated with acute,